Gilead Sciences Inc. paid President and CEO John Milligan about $15.4 million in total remuneration during 2017, up from about $13.9 million in 2016.
Milligan pocketed almost $1.55 million in base salary and $3.24 million in bonus payments, the company stated in a filing to the U.S. Securities and Exchange Commission.
That compares to $1.5 million in base salary and $2.61 million in bonus payments in 2016.
The California-based pharmaceutical giant's CEO received $4.89 million from stock awards and almost $5.75 million from option awards in 2017. In 2016, Milligan received about $4.35 million from stock awards and about $5.5 million from option awards.
Gilead's compensation committee had previously approved equity awards worth $11.5 million for Milligan in 2017 at its February 2017 meeting, compared to $11 million the previous year.
The ratio of Milligan's annual total compensation compared to Gilead's median employee's total annual compensation for fiscal year 2017 is 94 to 1.